(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class ...

Jefferies analyst Linda Tsai upgraded Kite Realty Group Trust (NYSE:KRG) shares to Buy from Hold on Thursday as the owner of shopping centers "is underappreciated given strength in the retail leasing ...

Jefferies downgraded Kite Realty (KRG) to Hold from Buy with a price target of $27, down from $31. The firm adjusted retail real estate investment trust ratings as a part of a 2025 outlook. Big Lots, ...

Detailed price information for Kite Realty Group Trust (KRG-N) from The Globe and Mail including charting and trades.

Raymond James downgraded Kite Realty (KRG) to Market Perform from Strong Buy without a price target Despite record levels of leasing across the ...

Kite Realty Group (KRG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Intriguingly, David Lamond’s Lamond Capital Partners dumped the biggest position of all the hedgies followed by Insider Monkey, comprising close to $6.4 million in stock, and Paul Marshall and Ian ...

In a report released today, Floris van Dijkum from Compass Point reiterated a Buy rating on Kite Realty Group (KRG – Research Report), with a price target of $29.00. The company’s shares closed ...

In a report released today, Anthony Powell from Barclays maintained a Buy rating on Kite Realty Group (KRG – Research Report), with a price target of $28.00. The company’s shares closed yesterday at ...

Aug 28 (Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive ...